endophthalmitis) are rare, but possible, adverse events associated with any intraocular surgery. Severe, vision threatening infections (e.g.
However, risks that come with invasive eye surgery are still significant and may include, but are not limited to infection, increased IOP, corneal edema, posterior capsular opacification (PCO), IOL decentration, macular edema, and retinal detachment. IOL implantation after cataract extraction, or as part of refractive lens exchange, is a relatively safe procedure. Higher order aberrations (HOAs) were noted to be 'not significant' with the Symfony IOL. In vitro analysis of the TECNIS Symfony and another EDOF IOL (not commercially available in the U.S.) demonstrated increasing negative spherical aberration with increasing pupil size for the Symfony IOL. ĭysphotopsias are multi-factorial, and may be pupil-dependent. Data from Alcon and clinic studies suggest that the Vivity IOL may have very low levels of potential glare and halos due to its novel design when compared with diffractive technology.
Near vision was acceptable (20/40 or better) for 40% of patients with the Vivity IOL (compared to 12% with the control).
#Amo back in focus trial#
In the same study, dysphotopsias (halos, glare, or starbursts) were reportedly low, with more than 90% of patients reporting no or mild halos, glare, starbursts, or other photic phenomena.įor the AcrySof™ IQ Vivity™ IOL, FDA trial data demonstrated was good distance vision (20/25 or better) for 89% of patients with the Vivity IOL (compared to 94% with the control monofocal IOL), good intermediate vision (20/25 or better) for 37% (40/107) of patients with the Vivity IOL (compared to 9% (10/113) with the control). Spectacle independence was high, with only 14.4% of eyes 011) were found in the monovision group than in the non-monovision group. The mean decimal uncorrected distance (UDVA), intermediate (UIVA), and near (UNVA) visual acuities were 0.95, 0.81, and 0.69, respectively, 4 to 6 months postoperatively. The mono-vision group was comprised of 112 patients, while the non-monovision group was made up of 299 patients. 411 patients who had bilateral implantation of the extended range of vision IOL, with intended micro-monovision in 1 group (monovision group) and intendedĮmmetropia in the other group (non-monovision group). Ī large prospective multi-center study demonstrated that the Symfony IOL provided comparable clinical outcomes in distance visual acuity to monofocal and current multifocal lens technologies, and possibly better intermediate visual acuity outcomes compared to current multifocal technology, with high levels of patient satisfaction. Additional studies have corroborated excellent UDVA with the Symfony IOL. OutcomesĪ recent comparative study found the Symfony IOL achieved significantly better postoperative uncorrected monocular and binocular distance (UDVA), intermediate (UIVA), and near (UNVA) visual acuities when compared to the monofocal Tecnis ZCB00 IOL (P ≥. Vivity uses a novel non-diffractive design, called X-WAVE™ technology.
The AcrySof™ IQ Vivity™ Extended Vision Intraocular Lens (IOL) became the second extended depth of focus lens to be FDA approved in the United States in March of 2020. In several studies, the Symfony IOL has performed similarly with monofocal and multifocal IOLs in regards to distance visual acuity results, with a trend toward superior uncorrected intermediate visual acuity, while multifocal IOLs have trended toward having superior uncorrected near visual acuity results. īoth multifocal and EDOF lenses have been shown to increase levels of spectacle independence, however both lens types may be associated with unwanted photic phenomena such as glare and halos. While still a diffractive optic, the extended foci allows for nearly all light to be transmitted through the IOL, with the reduction of chromatic aberrations. Its overall diameter is 13.0mm, with an optical zone of 6.0mm, and is available in power ranges from +5.0 to +34.0 D, while incorporating an ultraviolet light-absorbing filter. This proprietary format creates an achromatic diffractive pattern that elongates a single focal point and compensates for the chromatic aberration of the cornea. The IOL has a biconvex wavefront-designed anterior aspheric surface and a posterior achromatic diffractive surface with an echelette design (Figure 1). of Santa Ana, California, Now Johnson-Johnson Vision) was the first FDA approved lens of its class. Figure 1: Design and mechanism of action of extended range of vision TECNIS Symfony IOLĪs of July 15th 2016, the TECNIS Symfony IOL (Abbott Medical Optics/AMO, Inc.
0 kommentar(er)
